Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-78c5997874-4rdpn Total loading time: 0 Render date: 2024-11-19T06:27:57.396Z Has data issue: false hasContentIssue false

FLUVOXAMINE

Published online by Cambridge University Press:  03 May 2024

Stephen M. Stahl
Edited in association with
Jeffrey R. Strawn
Stephen M. Stahl
Affiliation:
University of California, San Diego
Jeffrey R. Strawn
Affiliation:
University of Cincinnati, Ohio
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Prescriber's Guide – Children and Adolescents
Stahl's Essential Psychopharmacology
 , pp. 261 - 272
Publisher: Cambridge University Press
Print publication year: 2024

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Suggested Reading

Bridge, JA, Iyengar, S, Salary, CB et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA 2007;297(15):1683–96.CrossRefGoogle ScholarPubMed
Carrillo, JA, Dahl, ML, Svensson, JO et al. Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity. Clin Pharmacol Ther 1996;60(2):183–190.CrossRefGoogle ScholarPubMed
Christensen, M, Tybring, G, Mihara, K et al. Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19). Clin Pharmacol Ther 2002;71(3):141–52.CrossRefGoogle Scholar
Croarkin, PE, Elmaadawi, AZ, Aaronson, ST et al. Left prefrontal transcranial magnetic stimulation for treatment-resistant depression in adolescents: a double-blind, randomized, sham-controlled trial. Neuropsychopharmacology 2021;46(2):462–9.CrossRefGoogle ScholarPubMed
Fung, R, Elbe, D, Stewart, SE. Retrospective review of fluvoxamine-clomipramine combination therapy in obsessive-compulsive disorder in children and adolescents. J Can Acad Child Adolesc Psychiatry 2021;30(3):150–5.Google ScholarPubMed
Hardy, NE, Walkup, JT. Clomipramine in combination with fluvoxamine: a potent medication combination for severe or refractory pediatric OCD. J Can Acad Child Adolesc Psychiatry 2021;30(4):273–7.Google ScholarPubMed
Hathaway, EE, Walkup, JT, Strawn, JR. Antidepressant treatment duration in pediatric depressive and anxiety disorders: how long is long enough? Curr Probl Pediatr Adolesc Health Care 2018;48(2):31–9.Google Scholar
Labellarte, M, Biederman, J, Emslie, G et al. Multiple-dose pharmacokinetics of fluvoxamine in children and adolescents. J Am Acad Child Adolesc Psychiatry 2004;43(12):1497–505.CrossRefGoogle ScholarPubMed
Mulder, H, Herder, A, Wilmink, FW et al. The impact of cytochrome P450-2D6 genotype on the use and interpretation of therapeutic drug monitoring in long-stay patients treated with antidepressant and antipsychotic drugs in daily psychiatric practice. Pharmacoepidemiol Drug Saf 2006;15(2):107–14.CrossRefGoogle ScholarPubMed
Reinblatt, SP, DosReis, S, Walkup, JT, Riddle, MA. Activation adverse events induced by the selective serotonin reuptake inhibitor fluvoxamine in children and adolescents. J Child Adolesc Psychopharmacol 2009;19(2):119–26.CrossRefGoogle ScholarPubMed
Riddle, MA, Reeve, EA, Yaryura-Tobias, JA et al. Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial. J Am Acad Child Adolesc Psychiatry 2001b;40(2):222–9.CrossRefGoogle ScholarPubMed
RUPP. Fluvoxamine for the treatment of anxiety disorders in children and adolescents. The Research Unit on Pediatric Psychopharmacology Anxiety Study Group. N Engl J Med 2001;344(17):1279–85.Google Scholar
Strawn, JR, Mills, JA, Poweleit, EA, Ramsey, LB, Croarkin, PE. Adverse effects of antidepressant medications and their management in children and adolescents. Pharmacotherapy 2023;43(7):675–90.CrossRefGoogle ScholarPubMed
Strawn, JR, Stimpfl, J. Optimizing benzodiazepine treatment of anxiety disorders. Curr Psychiatry 2023;22(6):22–33, 39.CrossRefGoogle Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • FLUVOXAMINE
  • Stephen M. Stahl, University of California, San Diego
  • Edited in association with Jeffrey R. Strawn, University of Cincinnati, Ohio
  • Book: Prescriber's Guide – Children and Adolescents
  • Online publication: 03 May 2024
  • Chapter DOI: https://doi.org/10.1017/9781009267526.029
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • FLUVOXAMINE
  • Stephen M. Stahl, University of California, San Diego
  • Edited in association with Jeffrey R. Strawn, University of Cincinnati, Ohio
  • Book: Prescriber's Guide – Children and Adolescents
  • Online publication: 03 May 2024
  • Chapter DOI: https://doi.org/10.1017/9781009267526.029
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • FLUVOXAMINE
  • Stephen M. Stahl, University of California, San Diego
  • Edited in association with Jeffrey R. Strawn, University of Cincinnati, Ohio
  • Book: Prescriber's Guide – Children and Adolescents
  • Online publication: 03 May 2024
  • Chapter DOI: https://doi.org/10.1017/9781009267526.029
Available formats
×